Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome

Clinical characteristics.

Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is a disorder of the urea cycle and ornithine degradation pathway. Clinical manifestations and age of onset vary among individuals even in the same family.

Neonatal onset (~8% of affected individuals). Manifestations of hyperammonemia usually begin 24-48 hours after feeding begins and can include lethargy, somnolence, refusal to feed, vomiting, tachypnea with respiratory alkalosis, and/or seizures.

Infantile, childhood, and adult onset (~92%). Affected individuals may present with:

• Chronic neurocognitive deficits (including developmental delay, ataxia, spasticity, learning disabilities, cognitive deficits, and/or unexplained seizures);
• Acute encephalopathy secondary to hyperammonemic crisis precipitated by a variety of factors; and
• Chronic liver dysfunction (unexplained elevation of liver transaminases with or without mild coagulopathy, with or without mild hyperammonemia and protein intolerance).

Neurologic findings and cognitive abilities can continue to deteriorate despite early metabolic control that prevents hyperammonemia.

Diagnosis/testing.

The biochemical diagnosis of HHH syndrome is established in a proband with the classic metabolic triad of episodic or postprandial hyperammonemia, persistent hyperornithinemia, and urinary excretion of homocitrulline. The molecular diagnosis of HHH syndrome is established in a symptomatic individual with or without suggestive metabolic/biochemical findings by identification of biallelic pathogenic variants in SLC25A15.

Management.

Treatment of manifestations: Acute and long-term management is best performed in conjunction with a metabolic specialist. Of primary importance is the use of established protocols to rapidly control hyperammonemic episodes by discontinuation of protein intake, intravenous infusion of glucose and, as needed, infusion of supplemental arginine and the ammonia removal drugs sodium benzoate and sodium phenylacetate. Hemodialysis is performed if hyperammonemia persists and/or the neurologic status deteriorates.

Prevention of primary manifestations: Individuals with HHH syndrome should be maintained on an age-appropriate protein-restricted diet, citrulline supplementation, and sodium phenylbutyrate to maintain plasma concentrations of ammonia, glutamine, arginine, and essential amino acids within normal range. Note: Liver transplantation is not indicated when metabolic control can be achieved with this regimen as liver transplantation may correct the hyperammonemia but will not correct tissue-specific metabolic abnormalities that also contribute to the neuropathology.

Surveillance: Routine assessment of height, weight, and head circumference from the time of diagnosis to adolescence. Routine assessment of plasma ammonia concentration, plasma and urine amino acid concentrations, urine organic acids, and urine orotic acid based on age and history of compliance and metabolic control. Routine developmental and educational assessment to assure optional interventions. Attention to subtle changes in mood, behavior, and eating and/or the onset of vomiting, which may suggest that plasma concentrations of glutamine and ammonia are increasing. Periodic neurologic evaluation to monitor for neurologic deterioration even when metabolic control is optimal.

Agents/circumstances to avoid: Excess dietary protein intake; nonprescribed protein supplements such as those used during exercise regimens; prolonged fasting during an illness or weight loss; oral and intravenous steroids; and valproic acid, which exacerbates hyperammonemia in urea cycle disorders.

Evaluation of relatives at risk: Once the pathogenic variants in a family are known, use molecular genetic testing to clarify the genetic status of at-risk relatives to allow early diagnosis and treatment, perhaps even before symptoms occur.

Pregnancy management: In general, pregnant women should continue dietary protein restriction and supplementation with citrulline and ammonia-scavenging medications based on their clinical course before pregnancy. Due to increased protein and energy requirements in pregnancy and, oftentimes, difficulty with patient compliance, weekly to every two-week monitoring of plasma amino acids and ammonia is recommended, especially in the first and third trimester, and close monitoring immediately after delivery.

Genetic counseling.

HHH syndrome is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the SLC25A15 pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible. However, the identification of familial SLC25A15 pathogenic variants cannot predict clinical outcome because of significant intrafamilial phenotypic variability.

Suggestive Findings

Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome should be suspected in symptomatic individuals with the following age-related clinical, laboratory, and neuroimaging findings.

Establishing the Diagnosis

Genotype-Phenotype Correlations

The SLC25A15 genotype does not correlate with the clinical or biochemical phenotype of HHH syndrome [Fiermonte et al 2003, Camacho et al 2006, Tessa et al 2009].

Nomenclature

The name "hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome" was coined by Vivian Shih, MD in 1969 for the disorder in which a "block in the ornithine metabolic pathway" has biochemical findings "not concordant with those in patients with proven hepatic ornithine transcarbamylase deficiency" [Shih et al 1969].

In 1999 after ORNT1 (now known as SLC25A15), the gene encoding ORNT1, was identified, the term ORNT1 deficiency was introduced and used interchangeably with HHH syndrome [Camacho et al 1999].

HHH syndrome may also be referred to as "ornithine transporter deficiency" or "ornithine translocase deficiency."

Clinical Description

Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is characterized by variable clinical presentation and age of onset ranging from the neonatal period to adulthood. Those with neonatal onset are normal for the first 24-48 hours, followed by onset of symptoms related to hyperammonemia (poor feeding, vomiting, lethargy, low temperature, rapid breathing). Those with later onset may present with chronic neurocognitive deficits and/or unexplained seizures, spasticity, acute encephalopathy secondary to hyperammonemic crisis, or chronic liver dysfunction. Neurologic findings and cognitive abilities can continue to deteriorate despite early metabolic control that prevents hyperammonemia.

Unless otherwise indicated, the data used in this chapter are from a total of 122 individuals with HHH syndrome: Martinelli et al 2015 (n=111), six subsequent case reports [Qadri et al 2016, Guan et al 2017, Ono et al 2018, Silfverberg et al 2018, Ho et al 2019, Wild et al 2019] and three unpublished affected individuals [Author, personal observation].

The overall survival rate in individuals with HHH syndrome is 94% (109/116). Of the 21% (13/62) of individuals with HHH syndrome who manifested in the neonatal period, the mortality rate is 15% (2/13). Treatment with a protein-restricted diet resolves hepatic dysfunction (elevated transaminases and coagulopathy). Since hyperammonemia in HHH syndrome responds quickly to treatment, early diagnosis leads to an overall improved long-term outcome regardless of the age of onset.

The long-term neurodevelopmental outcome usually (but not always) correlates with the severity and duration of the hyperammonemic insult.

Pyramidal tract findings and intellectual disability, which range from mild to severe, are generally evident by childhood since almost 70% of HHH syndrome manifests in infancy and childhood [Martinelli et al 2015]. While treatment with a protein-restricted diet prevents postprandial and acute hyperammonemia, outcomes vary. For example, individuals with HHH syndrome with limited clinical manifestations throughout life have been reported [Filosto et al 2013; Silfverberg et al 2018; L Merritt, MD & E Font-Montgomery, MD, personal communication (see Outcomes and Presentation; pdf). Conversely, three of four adults with HHH syndrome who maintained normal levels of plasma ammonia for 11 to 38 years exhibited progressive neurologic and cognitive deterioration with serious outcomes [Kim et al 2012].

Neonatal diagnosis (birth – 1 month). About 8% (9/116) of affected individuals were diagnosed during the neonatal period, usually following an uncomplicated pregnancy and delivery. The clinical course is indistinguishable from that of other neonatal-onset urea cycle disorders: the infant is asymptomatic for the first 24-48 hours and, thereafter, has episodes of poor feeding, vomiting, lethargy, low temperature, and/or rapid breathing related to hyperammonemia (see Table 1). If left untreated seizures, coma, and even death may ensue. Hepatic dysfunction and coagulopathy in the neonatal period are common [Martinelli et al 2015, Wild et al 2019].

Given the small number of case studies published to date, little is known about the long-term outcome of individuals with neonatal onset of HHH syndrome. One child died from hyperammonemic encephalopathy at birth and another at age two months. Survivors ranged in age from one to 23 years – one demonstrated normal development at age six years, four had progressive pyramidal signs, and one with significant neuromotor impairment underwent liver transplantation at age seven years. In eight survivors with neonatal onset, cognitive abilities in four ranged from normal to mild deficiency, three exhibited severe cognitive impairment, and one was a recently reported premature infant [Martinelli et al 2015, Wild et al 2019].

Click here (pdf) for more details about outcomes in the neonatal-onset cases described above.

Infantile (>1 month – 1 year) age at diagnosis. Approximately 10% (12/116) of individuals with HHH syndrome present in this timeframe. Highly variable manifestations in infancy can include hypotonia, lethargy, failure to thrive, seizures, psychomotor delay, hepatomegaly, hepatic dysfunction (coagulopathy and elevated transaminases), hyperammonemia, feeding difficulties, and recurrent vomiting. Some children come to medical attention only after experiencing environmental stressors, most commonly infection.

Unique case studies include an affected individual who presented with fulminant hepatic failure and a recent example of the clinical progression of symptoms in an undiagnosed infant.

Click here (pdf) for more details about the presentation of infantile-onset HHHS described above.

Childhood (>1 year to 12 years) presentation accounts for almost half (56/116) of all HHH syndrome. Children in this group come to medical attention either for findings related to mild hyperammonemia with or without liver dysfunction or for evaluation of developmental and speech delay, dysarthria, intellectual disability, learning disabilities, hyperactivity, recurring vomiting, academic difficulties, spasticity, ataxia, and/or unexplained seizure activity. Environmental triggers (i.e., surgery, infection, medication) may also induce manifestations in previously healthy children.

A salient characteristic of affected individuals diagnosed in childhood who harbor the same SLC25A15 pathogenic variants is marked phenotypic variability.

Click here (pdf) for more details about outcomes in childhood-onset HHHS.

Liver dysfunction, a predominant feature at time of diagnosis, generally manifests as mild coagulopathy and elevated liver enzymes (AST and ALT) with or without hyperammonemia. In a few reports acute liver failure prompted consideration of liver transplantation [Fecarotta et al 2006, Mhanni et al 2008]. However, the liver dysfunction that may occur during the initial clinical presentation does not appear to cause long-term complications. Once the hyperammonemia is treated in a standard manner (see Treatment of Manifestations), the liver dysfunction subsides [Martinelli et al 2015, Ono et al 2018].

Despite early detection and adequate metabolic control (i.e., absence of hyperammonemia), some individuals with HHH syndrome continue to worsen neurologically with pyramidal tract involvement and cognitive decline [Camacho et al 2006, Debray et al 2008, Tessa et al 2009, Martinelli et al 2015]. Subclinical hyperammonemia is thought to be a major factor in neurocognitive decline, but not in the cause or progression of pyramidal syndrome. In some individuals with early-childhood onset, gait abnormalities and spasticity are the predominant findings.

The Urea Cycle Disorders Consortium reported developmental quotients (DQ) in four preschool children (age 4-5 years) with HHH syndrome: two were in the normal range and two were <71. Two also exhibited anxiety and acting out behaviors [Waisbren et al 2016].

Adolescence/adulthood (>12 years) accounts for about one third (39/116) of persons with HHH syndrome. After infancy, these individuals quickly learn to self-restrict their protein intake to avoid the malaise and vomiting that accompanies protein-rich meals. The milder form of the disease and self-adherence to a low-protein diet allow these individuals to lead a relatively symptom-free life and remain undetected until they inadvertently overwhelm their compromised ability to detoxify harmful elevations of plasma ammonia. Ammonia overload may result from catabolic events (i.e., surgery, infection, prolonged fasting, pregnancy, internal bleeding), deviation from a protein-restricted diet, or certain medications (e.g., valproate, steroids).

Individuals diagnosed in adolescence/adulthood may present with recurrent encephalopathy secondary to hyperammonemia (lethargy, disorientation, episodic confusion, unexplained seizures), intellectual disabilities, recurrent vomiting, chronic behavioral problems, cerebellar signs (dizziness, loss of balance, poor coordination, abnormal gait/posture), and pyramidal tract dysfunction (inability to perform fine movements, positive Babinski reflex, muscle weakness, ataxia, hyperreflexia, and spasticity).

Click here (pdf) for more details about outcomes in adolescent/adult-onset HHHS.

Cognitive development in persons with HHH syndrome ranges from normal (34%) to severe impairment (34%), with the majority having normal to mild neurocognitive deficit (59%). In some reports, affected individuals have significant neurologic findings such as spasticity and ataxia without cognitive impairment [Martinelli et al 2015]. Of note, pyramidal signs of the lower extremities (hyperreflexia, clonus, tip-toe gait, and/or spastic ataxia) may develop years after the initial diagnosis [Salvi et al 2001b, Debray et al 2008, Tessa et al 2009].

The Urea Cycle Disorder Consortium reported findings of two successive neurocognitive evaluations given to one adult with HHH syndrome: full scale IQ was 100 and 84 at ages 21 years and 26 years, respectively; performance was significantly diminished across all neuropsychological tests. No cognitive or behavioral issues were noted [Waisbren et al 2016].

Additional clinical biochemical abnormalities in HHHS can include the following:

• Mildly elevated plasma glutamine concentration (1.5- to 2-fold the upper limits of control values)
• Plasma lysine can range from normal to moderately decreased
• Increased urinary excretion of:
  • Orotic acid (2.5- to 12-fold the upper limit of control values)
  • Organic acids. An increase in the urinary excretion of components of the Krebs cycle (succinate, citrate, fumaric, α-ketoglutaric), methylcitrate, and lactate has been documented in a few reports [Korman et al 2004, Fecarotta et al 2006].
• Statistically significant elevation of AFP and pronounced liver ultrasound abnormalities at follow up [Ranucci et al 2019]

Prevalence

Since the description of the first individual with HHH syndrome by Shih et al [1969], approximately 122 individuals with HHH syndrome have been reported [Martinelli et al 2015, Qadri et al 2016, Guan et al 2017, Ono et al 2018, Silfverberg et al 2018, Ho et al 2019, Wild et al 2019].

Summar et al [2013], using two large longitudinal registries in the US (NIH-sponsored Urea Cycle Disorders (UCD) Consortium and The National UCD Foundation) and one in Europe (European Registry and Network for Intoxication-Type Metabolic Diseases), calculated an incidence for HHH syndrome of 1% and 3% of all UCDs in the US and Europe, respectively. In the US, the frequency of HHH syndrome is less than 1:2,000,000 live births [Summar et al 2013].

The incidence of HHH syndrome is highest in individuals of French-Canadian ancestry because of the SLC25A15 founder variant c.562_564delTTC (p.Phe188del) in this population (see Table 8) [Camacho et al 1999, Debray et al 2008]. A study of this founder variant in an isolated northern Saskatchewan population of mixed French-Canadian and Aboriginal descent suggested that the incidence of HHH syndrome in this population is 1:1,550 live births [Sokoro et al 2010].

Another common pathogenic variant, c.535C>T (p.Arg179Ter) (see Table 8), seen in 14% of individuals with HHH syndrome, is frequent in persons with HHH syndrome of Japanese and Middle Eastern descent [Tsujino et al 2000, Salvi et al 2001a].

Hyperammonemia

Most commonly, neonates with hyperammonemia and neonatal-onset HHH syndrome are initially suspected of having sepsis. See Häberle et al [2019] for a comprehensive algorithm for the differential diagnosis of neonatal hyperammonemia based on plasma and urine metabolites.

Like other urea cycle disorders (UCDs), HHH syndrome should be included in the differential diagnosis of any individual with hyperammonemia, including women who experience hyperammonemia during or following pregnancy. The onset and severity of findings in HHH syndrome are more variable and less severe when compared to UCDs like ornithine transcarbamylase (OTC) deficiency or carbamyl phosphate synthase (CPS-I) deficiency (OMIM 237300). UCDs usually present with isolated elevation in plasma ammonia concentration and metabolic alkalosis. Plasma amino acid analysis and acylcarnitine profile, urine amino acid analysis, urine organic acid analysis, and urine orotic acid measurements allow diagnosis of the specific UCD (see Urea Cycle Disorders) or HHH syndrome. Neonates with a UCD may have hypoglycemia.

A complete chemistry panel (CMP), CBC and differential, lactate determination, arterial blood gases, serum creatine kinase (CK), and urinalysis (to check for ketonuria) should always be included in the evaluation of any person with an elevated plasma ammonia concentration to evaluate for conditions including the following:

• Organic acidemias (present with acidosis)
• Lysinuric protein intolerance (associated with low plasma ornithine, lysine, and arginine)
• Fatty-acid oxidation defects (associated with nonketotic hypoglycemia and liver dysfunction). See MCAD Deficiency.
• Pyruvate carboxylase deficiency (presents with lactic acidosis and hypoglycemia)
• Mitochondrial disease. Given that the neurologic nonacute presentation for HHH syndrome may be indistinguishable from primary mitochondrial disease, urine organic acid analysis should also be ordered. In some cases of HHH syndrome, urinary excretion of Krebs cycle components (succinate, fumarate, citrate, and α-ketoglutarate) and lactate have been reported [Korman et al 2004]. This pattern of excretion of organic acids, which is commonly seen in children and adults with defects in mitochondrial complex I or III, may create the impression that persons with HHH syndrome have a primary rather than a secondary mitochondrial defect.

Hyperornithinemia

The only other condition that causes chronic elevations in plasma ornithine concentration is deficiency of ornithine amino transferase (OAT) (OMIM 258870), a mitochondrial matrix enzyme involved in the ornithine degradation pathway. However, OAT deficiency never presents with the neurologic and clinical biochemical features of HHH syndrome (e.g., elevation in plasma ammonia concentration and glutamine, urinary excretion of homocitrulline and/or orotic acid). OAT deficiency presents mostly with ophthalmologic findings known as hyperornithinemia with gyrate atrophy of the choroid and retina that manifest as chorioretinal degeneration with loss of peripheral vision, night blindness, and often posterior subcapsular cataracts [Kim et al 2013].

Homocitrullinuria

Homocitrulline is a by-product of canned milk production that arises from the reaction of cyanate and the terminal ε-amino group of lysine. In canned formulas, cyanate is produced from heat-induced urea breakdown. When homocitrulline is consumed in the diet from sources such as these, it is absorbed in the small intestine via a transport system similar to that of cationic amino acids and excreted in the urine. In contrast, homocitrullinuria detected in neonates given IV glucose only (and no dietary source of protein) indicates the presence of a metabolic disorder.

Some individuals with lysinuric protein intolerance (LPI) have been shown to excrete homocitrulline [Habib et al 2013]. Although these individuals may also have hyperammonemia, their clinical biochemical profile demonstrates low concentrations of plasma ornithine, lysine, and arginine and persistent urinary excretion of lysine, ornithine, and arginine.

Neurologic Findings

In those individuals with early-childhood onset HHH syndrome in whom gait abnormalities and spasticity predominate, the differential diagnosis should also include early-onset inherited spastic paraplegia (see Hereditary Spastic Paraplegia Overview).

Arginase I deficiency is the only other urea cycle disorder (UCD) in which a prominent manifestation is progressive pyramidal tract involvement leading to spastic paraparesis. In general, spastic paraparesis in arginase I deficiency manifests earlier in childhood.

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs of an individual diagnosed with the hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to diagnosis) are recommended.

Treatment of Manifestations

It is critical that the acute and long-term management of individuals with HHH syndrome be performed in conjunction with a metabolic specialist. Of primary importance is the rapid control of acute hyperammonemic episodes that may result from changes in diet (e.g., protein intake), infection, dehydration, fasting, injury, or unknown cause. Long-term management focuses on prevention of postprandial hyperammonemia and acute hyperammonemic episodes and efforts to lower the plasma ornithine concentration.

Acute hyperammonemic episodes are treated like hyperammonemic episodes in other UCDs: assessment of plasma ammonia concentration, complete chemistry panel, arterial blood gases, CBC and differential (to evaluate for an infectious process), urinalysis, urine and plasma amino acids, and urine orotic acid. Urine organic acids should also be included to determine possible secondary mitochondrial dysfunction. Viral studies are indicated to evaluate infection as a possible cause of catabolism.

Plasma ammonia concentrations ≥80 μmol/L (~2x control value) should be treated immediately.

Discontinue all oral intake until the patient is stabilized to stop all protein intake (a cornerstone of acute treatment) and to reduce the risk of vomiting from hyperammonemia and/or nitrogen-scavenging medications. Of note, use of the recently approved ammonia-scavenging medication glycerol phenylbutyrate (RAVICTI^®) should be stopped as it relies on pancreatic lipases and, thus, only works when administered with food [Berry et al 2017].

Provide intravenous fluid with dextrose and intralipids to reverse catabolism while optimizing caloric intake:

• Initial intravenous infusion should be 10% dextrose (with 1/4 normal saline and 20 mEq/L KCl) at twice maintenance; ammonia and glucose/Na/K/Cl/CO₂ concentrations should be monitored every two hours or when neurologic status changes.
• It is important to maintain an approximate glucose infusion rate (GIR) between 10 to 15 mg/kg/min in order to prevent catabolism (protein sparring effect) and maintain adequate blood glucose levels between 100 and 150 mg/dL. The concentration of glucose may need to be increased (12.5% to 15%) to prevent fluid overload, particularly when secondary brain edema is present. As the patient's metabolic condition stabilizes, it is important to keep a stable GIR and not decrease or stop infusion rate in response to hyperglycemia (>150 mg/dL). An insulin drip should be used to maintain blood glucose at ~150-160 mg/dL during the critical phase of the hyperammonemic event and may be quickly withdrawn or reduced in rate if hypoglycemia develops.
• The use of IV intralipids (2-3 g/kg/day) is an additional source of energy used in patients with prolonged episodes of hyperammonemia common during periods of infection.
• An individual with HHH syndrome is more likely to respond to the initial IV infusion of dextrose and to normalize his/her plasma ammonia concentration when compared to an individual with a urea cycle disorder such as OTC deficiency or ASS deficiency. If clinical status does not improve, infusion of supplemental arginine and ammonia removal drugs is added to the regimen.

Of note, as clinical manifestations often do not correlate with rising plasma ammonia concentrations, treatment decisions should consider both plasma ammonia concentration and neurologic status.

Follow published protocols for treatment of acute hyperammonemic episodes similar to those instituted for OTC deficiency (see National Organization for Rare Diseases Physician Guide to the Urea Cycle Disorders) [Brusilow & Horwich 2001]. See also Häberle et al [2019] and Matsumoto et al [2019] for protocols specific to HHH syndrome. These protocols consist of arginine supplementation and use of intravenous bolus and maintenance infusions of the ammonia removal drugs sodium benzoate and sodium phenylacetate.

The New England Consortium of Metabolic Programs complete set of treatment protocols for neonatal hyperammonemia and OTC deficiency focusing on the use of Ammonul^® (Ucyclyd Pharma) are freely available. Alfadhel et al [2016] provide an excellent online step-by-step resource for management of hyperammonemia.

It is important to note that unless the patient is transferred to a specialized metabolic center, treatment with scavenging agents to remove excess nitrogen and ammonia from the blood will depend on availability of medications.

An initial priming dose of arginine, benzoate, and phenylacetate is given (see Table 5).

If ammonia levels stabilize, the same arginine, benzoate, and phenylacetate solution is infused over 24 hrs.

Note: All preparations of arginine and ammonia removal drugs should be double- or triple-checked given the potential for drug intoxication (if high doses are given) or for continued CNS ammonia toxicity (if low doses are given). If sodium benzoate or sodium phenylacetate solutions are not available, infusion of arginine should be started.

• Sodium phenylbutyrate (sodium phenylacetate prodrug) may be given either by mouth or by nasogastric tube (Buphenyl^® powder) during acute episodes of hyperammonemia in hospitals that do not carry IV Ammonul^® (sodium benzoate/phenylacetate). Moreover, in patients who use glycerol phenylbutyrate for maintenance at home, sodium phenylbutyrate should continue after formula and food are started until discharge to avoid double medication errors.
• Dose of sodium phenylbutyrate:
  • ≤25 kg: 550-600 mg/kg/day
  • >25 kg: 9.9-13.0 g/m²/day

Table 6 summarizes mechanisms of drug actions in the treatment of hyperammonemia.

Concurrent with the above, the trigger for the hyperammonemic event (most commonly infection or internal bleeding) should be identified and treated to prevent ongoing protein catabolism and allow for the metabolic stabilization of the patient.

Hemodialysis. If the patient fails to respond to the above treatment of hyperammonemia, if the plasma ammonia concentration increases, and/or if the neurologic status deteriorates, dialysis should be started promptly to remove ammonia from the circulation. Infusion of arginine, benzoate, and phenylacetate should continue during dialysis. The preferred method to remove increased levels of ammonia in neonates, infants, and children is continuous renal replacement therapy (CRRT), especially when there is hemodynamic instability [Häberle et al 2019, Matsumoto et al 2019].

Need for dialysis (CRRT) falls into one of the following three categories based on age and plasma ammonia level [Alfadhel et al 2016, Häberle et al 2019]:

• Neonates and children
  • Unlikely: <200 µmol/L
  • Possible: ≥200-300 µmol/L if no response within four hours
  • Definitely: >400-500 µmol/L
• Adolescents and adults. Definitely if ammonia >200µmol/L

Dialysis may be prolonged if the catabolic state (e.g., infection) persists.

Nutrition. Twenty-four to 36 hours after initial admission oral intake should start, including daily doses of only essential amino acids, carnitine, vitamins, and lipids to help avoid a catabolic state, which will prolong hyperammonemia. Note: Nonessential amino acids (i.e., glutamine, proline, and glycine) should be avoided since they increase the nitrogen load to an already compromised urea cycle.

Long-term management includes maintenance on an age-appropriate protein-restricted diet that controls hyperammonemia, but also provides sufficient protein for normal growth and development, especially for infants and children.

The recommended amount of total protein, calories, and fluids consumed per day varies with age. The ratio of natural protein to essential amino acids is approximately 60:40. The Ross Manual [Acosta & Yannicelli 2001] can serve as a guide for the recommended daily nutrient intake for infants, children, and adults. For example, patients age 12 yrs or older usually need approximately 0.7-1.0 g/kg/day of total protein.

• Dietary supplementation with Cyclinex^®-1 formula (infants and toddlers) or Cyclinex^®-2 formula (children, adolescents, and adults) that provides only essential amino acids and other nutritional supplements has been helpful for some patients. Children older than age 10-12 years and adults with a urea cycle disorder use VITAFLO^® essential amino acid supplement.
• Caloric supplements such as ProPhree^® (4.5 calories per gram) are available for neonates, infants, and toddlers.
• UCD-Trio^® provides isoleucine, leucine, and valine for toddlers and children whose branched-chain amino acid levels are consistently low, often due to ammonia-scavenging drugs.
• Citrulline supplementation at 0.17 g/kg/day or 3.8 g/m²/day is preferred to arginine because citrulline provides better metabolic control and avoids secondary creatine deficiency [Martinelli et al 2015]. Citrulline accepts an aspartate (via the arginosuccinate synthase reaction) and therefore eliminates two amino groups per cycle. Molema et al [2019] reported that in patients with OTC deficiency, CPS1 deficiency, or HHH syndrome, the relatively greater bioavailability of citrulline leads to higher plasma arginine levels than no supplementation or supplementation with arginine.
• Sodium phenylbutyrate (Buphenyl^®) is given in three divided doses either as 450-600 mg/kg/day for patients ≤25 kg or as 9.9-13.0 g/m²/day for patients ≥25 kg when glycerol phenylbuyrate (RAVICTI^®) is not available. Note that sodium phenylbutyrate initially is imported into the mitochondria where it undergoes β-oxidation to produce phenylacetate.
• Effective January 2019, the FDA approved the use of glycerol phenylbutyrate (RAVICTI^®, Horizon Pharma) for patients of all ages (including neonates) for treatment of hyperammonemic episodes due to urea cycle disorders [Author, personal communication].
• Lysine supplementation is indicated when plasma lysine concentrations are low. Low plasma lysine concentrations have been associated with delayed growth and development.
• Creatine supplementation has also been recommended in HHH syndrome and urea cycle disorders such as OTC and ASS deficiencies [Boenzi et al 2012]. In HHH syndrome, the synthesis of creatine from arginine is decreased due to ornithine inhibition of the first step, which depends on glycine transaminidase.
• Carnitine supplementation may be necessary due to carnitine deficiency secondary to dietary restriction (e.g., meat) and/or conjugation of carnitine with ammonia removal drug metabolites (phenylacetate).
• Plasma concentrations of ammonia, glutamine, arginine, ornithine, and essential amino acids (in particular lysine, isoleucine, leucine, and valine) should be maintained within the normal range.
  Note: (1) Although elevated plasma ornithine concentrations may decrease significantly if dietary management is followed, complete normalization of plasma ornithine concentration is rarely observed. (2) Even in the absence of hyperammonemic episodes, affected individuals may continue to develop neurologic complications such as spasticity or learning disabilities. Maintaining as low a level of plasma ornithine as possible by restricting protein intake could help prevent some of the progressive neurologic complications seen in these individuals [Valle & Simell 2001].

Three individuals with HHH syndrome who had acute fulminant hepatic failure and coagulopathy rapidly stabilized after protein restriction and arginine or citrulline supplementation [Fecarotta et al 2006, Mhanni et al 2008, Lee et al 2014].

Liver transplantation is not indicated when metabolic control can be achieved with diet, supplemental citrulline, and ammonia-scavenging medications. Because SLC25A15 and the ornithine degradation pathway are expressed in all tissues (e.g., brain, kidney) and most cell types (e.g., astrocytes, fibroblasts), liver transplantation may correct the hyperammonemia, but it will not correct tissue-specific metabolic abnormalities that also contribute to the neuropathology.

Two instances of liver transplantation for HHH syndrome were reported:

• A child age six years with a history of continued biochemical abnormalities, protein intolerance, developmental delay, and abnormal posture [Guan et al 2017];
• A child age seven years with poor metabolic control who had presented at age four weeks with hyperammonemic coma (plasma ammonia 2,300 µmol/L) [Verloo et al 2007].

Surveillance

All surveillance of patients with HHH syndrome (Table 7) should be a combined effort of the general pediatrician or adult practitioner and a metabolic team (metabolic geneticist, metabolic dietician, and social worker).

Agents/Circumstances to Avoid

Avoid the following:

• Excess dietary protein intake
• Nonprescribed protein supplements such as those used to increase size of skeletal muscle during exercise regimens
• Prolonged fasting during an illness or weight loss
• Use of oral and intravenous steroids
• Valproic acid, which induces and exacerbates hyperammonemia in urea cycle disorders
• Exposure to communicable diseases

Evaluation of Relatives at Risk

Testing of at-risk sibs is warranted to allow for early diagnosis and treatment.

If the SLC25A15 pathogenic variants in the family are known and if prenatal testing has not been performed on an at-risk sib, test for the familial SLC25A15 pathogenic variants in the newborn period while restricting the diet (≤1.2 g/kg/day protein using breastfeeding and a zero-protein formula) and monitoring plasma ammonia, plasma amino acids, and urine orotic acid.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

Ho et al [2019] reported pregnancy management and outcomes of four women with HHH syndrome: a patient of their own who had two pregnancies; and three women reported in the literature. They provide a systematic protocol for severe metabolic decompensation during pregnancy.

Management of the affected mother before and during pregnancy to achieve metabolic control to enable normal fetal growth and development. In general, pregnant women should continue dietary protein restriction and supplementation with citrulline and ammonia-scavenging medications (after an appropriate benefit/risk calculation) based on their clinical course before pregnancy. Protein restriction during pregnancy is challenging given the complications that commonly arise during pregnancy (i.e., nausea, vomiting, anorexia) plus the natural aversion to protein exhibited by individuals with HHH syndrome. Due to increased protein and energy requirements in pregnancy and, oftentimes, difficulty with patient compliance, weekly to every two-week monitoring of plasma amino acids and ammonia is recommended, especially in the first and third trimester, and close monitoring immediately after delivery. Plasma amino acid levels can help guide quick adjustments to diet in order to achieve normal plasma amino acid profiles that prevent catabolism and hyperammonemia while allowing for normal fetal growth and development. Protein intake during pregnancy varied from 0.8 g/kg/day to 1.3 g/kg/day (normal dietary reference intakes: 1.1 g/kg/day to 1.2-1.52 g/kg/day) [Ho et al 2019].

Delivery by cesarean section is recommended in order to optimize metabolic control.

Häberle et al [2019] provide a table detailing protein intake and extra energy requirements in pregnancy and lactation.

Management of metabolic complications during pregnancy in women with HHH syndrome. Complications related to HHH syndrome arose during pregnancy and delivery and in the immediate postpartum period in three of the four women reported by Ho et al [2019]. Mild hyperammonemic episodes and seizures during pregnancy were treated by adjustments to dietary protein intake (decrease) and anti-seizure medication (carbamazepine), respectively [Kim et al 2012, Ho et al 2019].

• One woman experienced mild hyperammonemia at the end of the first trimester of her first pregnancy. In her second pregnancy, she experienced metabolic decompensation (ammonia 295 µmol/L) prior to the second trimester and responded well to emergency treatment with Ammonul^® and arginine [Ho et al 2019].
• A second woman experienced mild hyperammonemia at the end of the first trimester of her first pregnancy, and developed petit mal seizures in the second trimester and elevations in ammonia (21-103 µmol/L) post partum. In her second pregnancy, she experienced hyperammonemia ten hours post-C-section delivery that responded to treatment with oral sodium benzoate and IV arginine. During her third pregnancy, she had a seizure.
• A third woman experienced mild elevation of plasma ammonia (43-126 µmol/L) during labor.

Normal pregnancy and delivery were documented in two women with HHH syndrome.

• One, diagnosed with HHH syndrome at age 13 years in the course of evaluation of an affected sib, was clinically asymptomatic before pregnancy. During the pregnancy, she was maintained on citrulline and an appropriate protein-restricted diet [Rebecca Mardach, MD, Kaiser Permanente, personal communication].
• The other, a woman age 22 years with no neurologic findings, had learned to self-restrict protein intake after severe protein intolerance in infancy [Ho et al 2019].

Fetal outcomes. Ho et al [2019] summarized the outcome of five previously reported infants born to three women with HHH who were primarily on dietary management or older ammonia-scavenging medications (lactulose) during pregnancy. Three of the five pregnancies resulted in healthy newborns.

• One female had intrauterine growth restriction (IUGR); development at age two years was normal.
• One of the neonates who had normal development at birth experienced transient respiratory distress requiring mechanical ventilation.

There are no well-controlled epidemiologic studies of the fetal effects of sodium benzoate, phenylacetate, or phenylbutyrate during human pregnancy, although there are several case reports.

• Redonnet-Vernhet et al [2000] reported a woman with symptomatic ornithine transcarbamylase (OTC) deficiency who was treated with sodium benzoate during the first 11 weeks of gestation and was subsequently transitioned to sodium phenylbutyrate for the remainder of pregnancy. She delivered a healthy female who continued to do well at age two years.
• Lamb et al [2013] reported another woman with symptomatic OTC who was treated throughout pregnancy with sodium benzoate (4 g/4x/day), sodium phenylbutyrate (2 g/4x/day) and arginine (300 mg/4x/day) who delivered a healthy, unaffected male who was doing well at age six weeks.
• Ho et al [2019] are the first to document the use of sodium phenylbutyrate throughout two sequential pregnancies in a woman with HHH syndrome:
  • In the first pregnancy sodium phenylbutyrate (5.5 g/4x/day) was used as maintenance therapy. This resulted in the delivery of a healthy female who was noted to have typical growth and development at age five years.
  • In the second pregnancy, emergency treatment with Ammonul^® (sodium phenylacetate/sodium benzoate) to manage hyperammonemic crisis (ammonia 295 µmol/L) was used in addition to maintenance therapy of sodium phenylbutyrate (5 g/4x/day).
    Although the mother responded well to emergency treatment, the baby experienced IUGR and remained in the NICU due to prematurity and low birth weight. At age two years the child exhibited speech delay and autism.
    How severe metabolic decompensation, elevated plasma ornithine, and/or side effects of sodium phenylbutyrate, phenylacetate, and/or benzoate may have contributed to the speech delay and/or autism is not known.
• Ho et al [2019] prefer and recommend the use of sodium benzoate if deemed medically necessary during pregnancy, but did not advise switching maintenance medications during pregnancy

Theoretic concerns. Sodium benzoate has been reported to lead to malformations and neurotoxicity/nephrotoxicity in zebrafish larvae [Tsay et al 2007]. As a known differentiating agent, sodium phenylbutyrate also functions as a histone deacetylase (HDAC) inhibitor with potential teratogenicity given its ability to alter gene expression in fetal mice [Di Renzo et al 2007]. Theoretically, the use of benzoate/phenylacetate and in particular sodium phenylbutyrate should be avoided during pregnancy, especially during the first trimester. The use of these medications should be carefully evaluated for each individual (benefit/risk ratio) in consultation with a metabolic genetics specialist.

See MotherToBaby for further information on medication use during pregnancy.

Therapies Under Investigation

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.